Literature DB >> 8387422

A comparison of a specialist women's alcohol and other drug treatment service with two traditional mixed-sex services: client characteristics and treatment outcome.

J Copeland1, W Hall, P Didcott, V Biggs.   

Abstract

Eighty subjects from a specialist women's service (SWS) and eighty subjects from two traditional mixed-sex treatment services (TMS) were recruited to a comparative, longitudinal study of changes in alcohol and other drug associated problems. Both the SWS and the TMS programs were principally based on the traditional disease model and the 12-step philosophy but the SWS employed only female staff and provided residential childcare. The SWS succeeded in attracting significantly more lesbian women, women with dependent children, women sexually abused in childhood and with a maternal history of substance dependence than the TMS. Six months following treatment there were no significant differences in any measure of treatment outcome between the two treatment groups. The results suggest that the simple provision of women-only treatment and childcare without changing treatment content does not substantially improve treatment outcome in women with severe alcohol and other drug related problems.

Entities:  

Mesh:

Year:  1993        PMID: 8387422     DOI: 10.1016/0376-8716(93)90025-l

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  11 in total

Review 1.  Substance abuse treatment entry, retention, and outcome in women: a review of the literature.

Authors:  Shelly F Greenfield; Audrey J Brooks; Susan M Gordon; Carla A Green; Frankie Kropp; R Kathryn McHugh; Melissa Lincoln; Denise Hien; Gloria M Miele
Journal:  Drug Alcohol Depend       Date:  2006-06-08       Impact factor: 4.492

2.  Substance abuse treatment for women: changes in the settings where women received treatment and types of services provided, 1987-1998.

Authors:  Christine E Grella; Lisa Greenwell
Journal:  J Behav Health Serv Res       Date:  2004 Oct-Dec       Impact factor: 1.505

3.  Direct-to-Consumer Marketing: A Complementary Approach to Traditional Dissemination and implementation Efforts for Mental Health and Substance Abuse Interventions.

Authors:  Sara J Becker
Journal:  Clin Psychol (New York)       Date:  2015-03-01

4.  Pregnant women in women-only and mixed-gender substance abuse treatment programs: a comparison of client characteristics and program services.

Authors:  Yih-Ing Hser; Noosha Niv
Journal:  J Behav Health Serv Res       Date:  2006-10       Impact factor: 1.505

Review 5.  Alcohol use disorders in primary care: do gender-specific differences exist?

Authors:  Rebecca S Brienza; Michael D Stein
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

6.  Patient and program costs, and outcomes, of including gender-sensitive services in intensive inpatient programs for substance use.

Authors:  Sarah E Hornack; Brian T Yates
Journal:  Eval Program Plann       Date:  2017-09-01

7.  Gestational age at enrollment and continued substance use among pregnant women in drug treatment.

Authors:  Mishka Terplan; Joanne Garrett; Katherine Hartmann
Journal:  J Addict Dis       Date:  2009

8.  Do women with complex alcohol and other drug use histories want women-only residential treatment?

Authors:  Joanne Neale; Charlotte N E Tompkins; Alison D Marshall; Carla Treloar; John Strang
Journal:  Addiction       Date:  2018-01-24       Impact factor: 6.526

9.  Effectiveness of psychosocial interventions for reducing parental substance misuse.

Authors:  Ruth McGovern; James J Newham; Michelle T Addison; Matthew Hickman; Eileen Fs Kaner
Journal:  Cochrane Database Syst Rev       Date:  2021-03-16

Review 10.  A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people.

Authors:  Michael King; Joanna Semlyen; Sharon See Tai; Helen Killaspy; David Osborn; Dmitri Popelyuk; Irwin Nazareth
Journal:  BMC Psychiatry       Date:  2008-08-18       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.